Four years after the release of guidelines for pre-exposure prophylaxis (PrEP), a crucial tool in India’s fight against HIV, its accessibility remains significantly limited. While PrEP has proven to be an effective method for preventing HIV infection, its rollout in India is still in its infancy, leaving many at risk without access to this vital medication.
PrEP is a prescription medication that can reduce the risk of contracting HIV from sexual contact and injection drug use by up to 99% when taken consistently. Despite this effectiveness, the National AIDS Control Organisation (NACO) has yet to implement a public rollout of PrEP since issuing its guidelines in 2022. Currently, the medication is available at market prices, which can be prohibitively expensive for many, or through a few non-profit organizations offering subsidized options in select cities.
Recent developments in HIV prevention globally have included the approval of a long-acting injectable form of PrEP by the United States Food and Drug Administration (FDA). This injectable option, lenacapavir, is designed for those who struggle with the daily regimen of oral PrEP. The World Health Organization (WHO) has recommended rapid rollout of this injectable option across low- and middle-income countries, including India, to enhance accessibility.
The Current State of HIV in India
India has made significant strides in controlling the HIV epidemic since the first cases were identified in 1986. According to the ‘Sankalak, Status of National AIDS and STD Response Report 2024’ released by NACO, HIV prevalence among adults aged 15-49 was 0.20% in 2023, marking a 44% decline since 2010. However, the prevalence rate has plateaued in recent years, indicating the require for revitalized strategies to combat the epidemic.
While the overall incidence of HIV in the general population is low (0.05 per 1,000 uninfected persons), certain high-risk groups continue to experience significantly higher rates. For instance, men who have sex with men (MSM) report an incidence rate of 1.55, while transgender individuals face a rate of 2.76, and people who inject drugs (PWID) have a staggering incidence of 34.19. These statistics underscore the critical need for targeted interventions and access to preventive measures like PrEP for vulnerable populations.
Challenges in Accessing PrEP
Despite the availability of PrEP, its uptake in India has been hampered by several factors, including high costs and low awareness among at-risk populations. The monthly cost of PrEP can range from ₹2,200 to ₹3,000, which is a significant barrier for many individuals. The requirement for initial counseling and screening for HIV and other sexually transmitted infections adds to the financial burden.
Currently, few non-profit organizations offer PrEP at subsidized costs. For example, some organizations provide a month’s dose for as low as ₹400, which is significantly more affordable than market rates. However, misinformation about PrEP and its effectiveness persists, with many healthcare providers lacking sufficient knowledge about the medication. This gap in understanding creates additional challenges for individuals seeking to utilize PrEP for HIV prevention.
The Impact of Chemsex on HIV Risk
A rising trend among MSM and transgender individuals is the practice of chemsex, which involves the use of stimulants during sexual activity. According to public health experts, chemsex is not only sought for enhanced sexual experiences but also as a means to cope with mental health issues stemming from trauma and stigma. This practice can lead to inconsistent condom use and increased risk of HIV transmission, further emphasizing the need for effective prevention tools like PrEP.
Despite the guidelines established by NACO for PrEP distribution, implementation has been slow. The guidelines proposed a risk-scoring system for assessing eligibility and maximizing the cost-effectiveness of PrEP distribution. However, a lack of action on these recommendations has left many high-risk individuals without access to this essential medication.
Looking Ahead
As India grapples with the complexities of HIV prevention, the future of PrEP access remains uncertain. The lack of a comprehensive public health strategy has led to a situation where awareness and usage of PrEP are largely confined to urban centers and the privileged. However, studies indicate that once informed, many individuals in high-risk groups express a willingness to use PrEP, highlighting the potential for increased uptake if barriers to access can be addressed.
With the introduction of injectable PrEP, there is hope for improving accessibility and adherence among populations at risk. This recent formulation could alleviate some challenges associated with daily pill regimens, yet it also requires careful implementation and education to ensure that individuals understand its benefits and limitations.
Moving forward, it is crucial for public health authorities to prioritize the rollout of PrEP, particularly focusing on high-prevalence areas and vulnerable populations. Enhanced education, subsidized access, and community engagement will be essential in combating the HIV epidemic and ensuring that preventive measures like PrEP are available to all who need them.
As India continues its fight against HIV, it is imperative to foster open dialogues about sexual health and provide robust support systems for those at risk. The importance of community awareness cannot be overstated, as informed individuals are more likely to seek out and utilize preventive measures effectively.
For ongoing discussions and updates on HIV prevention initiatives, readers are encouraged to share their thoughts and experiences in the comments below.
This article is for informational purposes only and does not constitute medical advice. For health-related inquiries, please consult a healthcare professional.
